HYBRID EVENT: You can participate in person at London, UK or Virtually from your home or work.
ICC 2023

Sherif Salah

Sherif Salah, Speaker at Cancer Events
Private Research Center, Egypt
Title : Novel revolution in diagnosis and therapy of breast and prostate cancer


New cancer markers have been discovered in the form of male and female oncogene peptide protein and its anti-peptide antibodies. They were found in both salvia and blood samples of females with breast cancer and a male with prostate cancer, in a pilot study for fifteen married patients having cancer in advanced-stage and their Husbands and Wives. Ten females, their age ranging from 32 to 58 for breast cancer (group A), five males for prostate cancer their age ranging from 54 to 71 years (group B), and four normal persons [two male and two female], their age ranging from 23 to 34 years] (as control group), were recruited into a controlled study to investigate the presence of the new suspected oncogene peptide proteins and their specific anti-oncogene antibodies in their blood and saliva. Tumor markers, C.T scan, ultrasound, and mammogram reports were completely collected before the study for each subject in the three groups. The collection data revealed the presence of male oncogene peptide protein [MOP] in serum and saliva samples of male Husbands in group A and its specific anti-oncogene antibodies [AMOP] in the serum samples of each female affected with breast cancer in group A, and the presence of female oncogene peptide protein [FOP] in all five female Wives and its specific anti-oncogene antibodies [AFOP] in each male affected with prostate cancer in group B, and the differences between normal controls and cancer patients were estimated by different in vitro and in vivo experimental trails. Our conclusions showed that a direct relation exists between the increases in concentration levels of OPP and its AO Abs, and the stage of malignancy. These promising results can open the doors for a new challenge, by developing a therapeutic and prophylactic cancer vaccine as well as new biological markers for breast and prostate cancer.